INHIBITORS OF MICRORNAs miR-155, miR-103, miR-105 and miR-107 THAT REGULATE PRODUCTION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AS THERAPEUTICS AND USES THEREOF

摘要

Provided herein are methods, kits and compositions to increase ANP levels in a subject for the treatment of hypertension and/or cardiovascular diseases, comprising at least one anti-miR agent that inhibits at least one of, or a combination of miR-103, miR-105, miR-107 and/or miR-155, alone, or in combination with an inhibitor of miR-425. Anti-miR agents can be small molecules or an oligonucleotide complementary to at least part of the sequence of hsa-miR-103, hsa-miR-105, hsa-miR-107 and/or hsa-miR-155, or their respective seed sequences or.their binding site in the 3'UTR of NPPA gene. Also provided herein are methods, kits and compositions to decrease ANP levels in a subject for the treatment of low blood pressure, comprising at least one or a combination of agonists of miR-103, miR- 105, miR- 107 and/or miR-155, alone or in combination with a miR-425 agonist.